Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Adicet Bio Inc ACET

Healthcare Biotechnology
Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the... see more

Recent & Breaking News (NDAQ:ACET)

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 30, 2022

Adicet Bio to Present at Upcoming Investor Conferences

Business Wire September 7, 2022

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 31, 2022

Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates

Business Wire August 10, 2022

Adicet Bio to Present at Upcoming Investor Conferences

Business Wire August 1, 2022

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 29, 2022

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 1, 2022

Adicet Bio to Present at Upcoming Investor Conferences

Business Wire June 21, 2022

Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting

Business Wire June 6, 2022

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 3, 2022

Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)

Business Wire May 26, 2022

Adicet Bio to Present at Upcoming Investor Conferences

Business Wire May 18, 2022

Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates

Business Wire May 12, 2022

Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies

Business Wire May 5, 2022

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Business Wire May 4, 2022

Adicet Bio Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire April 27, 2022

Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001

Business Wire April 19, 2022

Adicet Bio to Participate in Upcoming Investor Conferences

Business Wire April 7, 2022

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 1, 2022

Adicet Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress

Business Wire March 15, 2022